The agreement gives Merck exclusive ex-US rights to ompenaclid – an oral inhibitor of the creatine transport channel SLC6A8 – as well as options to co-develop and co-promote the drug in the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback